The Importance of CRO Experience and Capabilities in Cancer Research
On this World Cancer Day, we celebrate the remarkable progress made in the fight against cancer and the crucial role that contract research organizations (CROs) like IITRI play in this global effort. Since our inception in 1936 as the research arm of the Illinois Institute of Technology (IIT), IITRI has been a trusted center of excellence in preclinical research and clinical trial sample analysis. With a dedicated cancer research program established in 1957, IITRI has been instrumental in evaluating the efficacy and safety of cancer therapies, contributing to over 250 publications in cancer drug discovery and development. This legacy of scientific rigor and dedication has positioned IITRI as a leader in the field, driving forward monumental efforts in developing effective cancer treatments.
One of IITRI’s most impactful collaborations has been with the National Cancer Institute (NCI). For decades, IITRI has served as a major preclinical contractor, conducting extensive carcinogenicity studies that are vital for the development of new cancer treatments. These studies, which include both traditional two-year rodent bioassays and accelerated six-month transgenic mouse studies, help determine the tumorigenic potential of novel therapeutics. IITRI’s expertise is highlighted by its completion of the largest single-agent carcinogenicity study ever performed for the National Toxicology Program, involving approximately 3,000 animals. This partnership underscores IITRI’s commitment to advancing cancer research through meticulous and groundbreaking preclinical work.
Universities and scientific nonprofits also play a pivotal role in cancer research. Institutions like the National Cancer Institute and universities across the globe drive the cancer research enterprise by supporting and convening researchers, funding facilities and systems, and coordinating national cancer programs
Nonprofits such as the American Cancer Society (ACS) and the Leukemia & Lymphoma Society (LLS) provide significant funding for innovative research projects that have the potential to revolutionize cancer treatment. These organizations ensure that funds are allocated to the most promising studies, enabling researchers to pursue ambitious projects and gather comprehensive data. By fostering collaboration and providing essential resources, universities and nonprofits help accelerate the discovery of new cancer therapies and improve patient outcomes.
As we honor World Cancer Day, it’s essential to recognize the invaluable contributions of CROs, universities, and scientific nonprofits in the battle against cancer. Through rigorous preclinical testing and safety evaluations and partnering with pharmaceutical and biotechnology companies, as well as government agencies, IITRI continues to drive innovation and progress in cancer research through carcinogenicity and immuno-oncology studies. Together, we can envision a future where cancer is no longer a formidable adversary but a condition that can be effectively managed and treated. Let’s celebrate the strides we’ve made and look forward to a brighter, cancer-free future.
About IITRI
IITRI is a mid-sized preclinical CRO (100,000 sq./ft. laboratory) that provides full GLP toxicology studies to satisfy IND/NDA submissions. This include inhalation as a route of exposure. We also provide infectious disease efficacy studies, immunology, biodistribution, vaccine studies, bioaerosol challenges (BSL-2/3) and complete analytical/bioanalytical support for all studies and clinical trials. Our smaller size and highly experienced staff (ave. tenure > 10 yrs) enables us to provide a customer-centric experience including guidance throughout the entire non-clinical process. Reach out to us today to learn how we can best support your program needs.
Recent Comments